Gemcitabine: monochemotherapy of breast cancer
1Department of Oncology, I.O.V., Ospedale Civile, Via Tre Martiri, 45100 Rovigo, Italy. icc.secretariat@azisanrovigo.it
Background:
Gemcitabine is a nucleoside analogue with proven activity in advanced and metastatic breast cancer. Its action is associated with a favourable toxicity profile which is mainly hematological. Its unique mechanism of action along with not overlapping toxicity is particularly useful both in combination treatment with other active drugs and a sequential therapy in the palliative setting.
Design:
Phase II studies of gemcitabine performed over the last decade were reviewed.
Results And Conclusions:
Despite some conflicting results in some trials, gemcitabine confirmed to be a useful drug to treat this condition.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules
